The role of Interleukin 6 inhibitors in therapy of severe COVID-19
Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases or treatment of malignancies; it may also appear during the progression of COVID-19. CSS is caused by dysregulation of the synthesis of cytokines, including pro-inflammatory, regulatory, and anti-inflammatory cyto...
Main Authors: | E. Nasonov, M. Samsonov |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-11-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222030891X |
Similar Items
-
IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6
by: E. L. Nasonov
Published: (2020-06-01) -
Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome
by: Luke Y.C. Chen, et al.
Published: (2021-05-01) -
Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
by: Pranay Sinha, et al.
Published: (2020-10-01) -
Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19
by: Jan Brábek, et al.
Published: (2020-10-01) -
Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
by: Steven Douedi, et al.
Published: (2020-01-01)